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In this issue of Clinical Microbiology and Infection, Rieg et al. [1] report on the 
role of  combination therapy in patients with Staphylococcus aureus bacteraemia. In 
patients with implanted devices, they observed less late complications related to 
S.aureus bacteraemia with combination therapy (4.5% [9/202]) than with 
monotherapy (10.6% [15/142], p=0.03). Most of the patients in the former group were 
treated with a rifampin combination. These results trigger the discussion on rifampin 
in orthopaedic-device related infections (ODRIs). In this commentary, we discuss 
three frequently asked questions. First, should rifampin be added to the anti-
staphylococcal treatment in patients with orthopaedic implants and S.aureus 
bacteraemia? Second, at which time should rifampin be started in patients with 
established ODRI after debridement or replacement surgery? Third, what is the 
optimal rifampin dose in ODRI? Because it is unlikely that randomized controlled 
trials investigating these questions will be performed, our viewpoints are presented 
here. 
Several studies have shown a high seeding rate to orthopaedic devices 
following community-acquired S.aureus bacteraemia, ranging from 30% to 40%. In 
contrast, the risk of ODRI is markedly lower following hospital-acquired S.aureus 
bacteraemia [2]. This points towards the importance of early anti-staphylococcal 
treatment, since the duration of bacteraemia prior to antimicrobial treatment is 
generally longer in community-acquired than in hospital-acquired sepsis. 
Asymptomatic haematogenous seeding to an implant may already have occurred 
when a patient with community-acquired S.aureus bacteraemia is seeking for medical 
help. If patients with occult ODRI are treated with rifampin combinations for S.aureus 
bacteraemia, the clinical diagnosis may be delayed without elimination of the biofilm 
infection. Therefore, we do not recommend routine adjunctive rifampin treatment in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3  
 
patients with S. aureus bacteraemia. Since rapid detection and surgical debridement 
is needed to cure ODRI with implant retention [3], delayed diagnosis should be 
avoided. Therefore, after S.aureus bacteraemia, body sites with orthopaedic devices 
must be carefully and repeatedly examined for clinical signs of infection. Upon 
suspicion of ODRI, rapid diagnostic work-up is required. 
The optimal time point for starting rifampin therapy in patients with 
staphylococcal ODRI is still a matter of debate between physicians prescribing it 
early in the treatment course (i.e., immediately after surgery), and those 
recommending a delayed treatment start (i.e., after all drains have been removed and 
the wound is dry). Choosing the optimal time for starting the antibiofilm treatment with 
rifampin is particularly important in patients with acute ODRI treated either with 
debridement and implant retention or one-stage exchange. There are several 
arguments for starting rifampin treatment early. After initial attachment of 
staphylococci to foreign body surfaces, the process of biofilm formation via cell-cell 
adhesion and matrix elaboration starts. In-vitro studies have shown, that this process 
is initiated within a short period of time after surface contact [4]. Taking in account 
that minimal biofilm eradication concentrations (MBECs, also called biofilm MBC) of 
bacteria are considerably higher than their corresponding minimal inhibitory 
concentrations (MICs), and that rifampin has good activity on susceptible biofilm 
staphylococci [5], early start of rifampin after bacterial adhesion to the implant may be 
advantageous. Nonetheless, we prefer not to start rifampin in the early course of 
infection, for the following reasons. First, the use of rifampin is endangered by 
emergence of rifampin resistance. The risk is highest, when administrating rifampin 
either as monotherapy or to an infectious focus containing a high bacterial load [6]. In 
the same line of reasoning, the newly published guidelines for staphylococcal 
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prosthetic valve endocarditis recommends the delay of rifampin treatment until blood 
cultures have turned negative [7]. Similarly, in orthopaedic surgery, the upcoming 
course of additional interventions (e.g., removal of haematoma, second look surgery 
because of persistent wound secretion) is difficult to estimate shortly after the first 
surgery. In early postoperative period, the bacterial load is unpredictable, but 
probably still high in case of debridement and implant retention. Second, rifampin 
penetrates well into all body fluids. Therefore, the skin microbiome is rapidly modified 
by antimicrobial therapy, and it is conceivable that patients treated with rifampin will 
select rifampin-resistant staphylococci [8]. Drainages in close proximity of the device 
and oozing wounds may therefore facilitate exogenous superinfection by rifampin-
resistant staphylococci from the skin microbiome. For these arguments, in patients 
with staphylococcal ODRI, we do not administer rifampin before all drains are 
removed, the wound is dry, and the bacterial load is lowered by debridement surgery 
and initial antimicrobial therapy with a standard iv-regimen (e.g., 3 – 5 days after 
surgery). A retrospective multicentre search for rifampin-resistant staphylococci 
causing PJI revealed that 44 of 48 cases had a previous episode of PJI, and 93 % of 
these had been treated with rifampin. This case-control study demonstrates that 
starting rifampin therapy when bacterial load is still high, and multiple previous 
surgical revisions are independent risk factors for developing a secondary PJI with 
rifampin-resistant staphylococci [9]. These observations suggest that the previously 
raised concern of early rifampin treatment regarding the possible emergence of 
resistance should be avoided.  
In different clinical studies, various doses and/or intervals of rifampin have 
been used, namely 900 mg once daily, 450 mg twice daily, 600 mg once daily, or 
300mg twice daily. In a neutropenic murine infection model with S.aureus isolates, 
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PK/PD indexes which best predict rifampin efficacy are a concentration-dependent 
killing (Cmax/MIC) and the area under the curve (AUC)/MIC [10]. Furthermore, 
rifampin has a long post-antibiotic effect in a S. aureus biofilm infection mouse model 
[11]. The AUC0-24h between 900 mg once daily and 450 mg twice daily does likely not 
significantly influence the AUC/MIC ratio. Though, in our experience, 450 mg twice 
daily is better tolerated than 900 mg once daily. This in particular important when 
considering that in ODRI the compound is commonly administered for 6 to 12 weeks 
or even longer. It is uncertain, whether once or twice daily dosing matters after a 
steady state has reached, since all of the above mentioned regimens have shown 
clinical efficacy. In our view, it is clinically useful to start treatment at high dose (e.g., 
450 mg twice daily), and reduce the dose in case of intolerance. Severe nausea, 
frequently occurring in the elderly, does not respond to antiemetic drugs. In a trial on 
the role of rifampicin in staphylococcal ODRI, severe nausea was observed in 17% of 
the patients treated with 450 mg twice daily [3]. In these patients, rifampin therapy 
could be continued after temporary stop with a reduced dose of 300 mg twice daily, 
indicating that these adverse events are – as observed in patients with anti-
tuberculous treatment – dose dependent.  
In contrast to the AUC0-24h, Cmax likely differs between once and twice daily 
regimens. However, even when considering Cmax/MIC or Cmax/MBEC as efficacy 
variable, there are in vitro arguments and mathematical extrapolations supporting 
that 300 mg twice daily may be as efficient as 600 mg once daily. Cmax in adults with 
tuberculosis treated with 300 mg rifampin once daily is approximately 6.6 (range 2.9 
– 14) µg/mL [12]. In six elderly male nursing home residents who received 300 mg 
rifampin orally every 12 hours for 14 days (in addition to ciprofloxacin), Cmax after 
dose 12 and 27 were 9.4 ± 3.1 and 7.3 ± 2.3 µg/mL, respectively [13]. Rifampin 
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bone/serum concentration ratios of 0.2–0.5 are found in humans (reviewed in [14]). 
Thus, calculated Cmax in bone are 1.3 – 4.5 µg/mL (range of medians, total range 0.6 
– 6) µg/mL. Though, this calculation does not take into account the accumulation in 
bone, since distribution in and elimination from various comportments is not linear 
[15]. Nonetheless, most staphylococci have a MIC for rifampin of ≤0.064 µg/mL. 
There is no uniformly accepted microbiological method for determining MBECs. Many 
‘biofilm’ staphylococci have a minimal bactericidal concentration of ≤2 µg/mL, and in 
combination with another compound, rifampin is active against the majority of these 
isolates [5]. Thus, it is likely that bone levels of rifampin with 300 mg twice daily are 
high enough to potentially cure the infection. Therefore, we recommend a delayed 
treatment start of adjunctive rifampin in staphylococcal ODRI with 450 mg twice daily; 
in case of intolerance, we recommend reducing the dose to 300 mg twice daily.  
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